Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and ...
Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.
January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
LEO Pharma and non-profit organisation DEBRA Research have announced a collaboration aimed at accelerating the development of treatments for epidermolysis bullosa (EB). The non-exclusive strategic ...
DEBRA Research GmbH, a non-profit organization dedicated to advancing research, advocacy, and support for those affected by epidermolysis bullosa (EB) and LEO Pharma, a global leader in medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results